Member Info for kezzman

Certainly

AIM only has five companies with approved drugs and Amryt is one of them We could sell are approved drug to any of the majors for substantially more than the current mcap "Tonnes of newsflow for summer/autumn." Cathal Martin Friel has £1.5million in at 4p. Tick tock boom

A highly experienced management team - The New Board and senior management is comprised of experienced industry participants including: · Harry Stratford, Chairman, is the founder of Shire plc, now a FTSE 100 biopharmaceutical company, and ProStrakan Group plc · Joseph Wiley, CEO, has over 20 years' experience in healthcare investment and pharmaceutical operational roles · Rory Nealon, CFO and COO, has spent the last 13 years as both CFO and then COO of Trinity Biotech PLC, a NASDAQ listed company · Michele Bellandi, CCO, is the former Head of Commercial Europe for Shire AG International and has held senior marketing roles at Serono and Eli Lilly · Ray Stafford, a Non-Executive Director, previously EVP of Global Marketing for Forest Laboratories which was listed on NYSE prior to being acquired for approximately US$28 billion · James Culverwell, a Non-Executive Director, previously head of European pharmaceutical equity research at Merrill Lynch in London until 2005. Current Directors Cathal Martin Friel (aged 51), Non-Executive Chairman and proposed Non-executive Director Mr Friel is managing director and one of the founders of Raglan Road Capital Limited (which trades as Raglan Capital), a Dublin and London based corporate finance and merchant banking group. Mr Friel has over 25 years of managerial, entrepreneurial and corporate finance experience, as well as successfully advising major UK and Irish companies on domestic and international transactions. He was previously one of the founding directors of Dublin based Merrion Corporate Finance, where he helped build Merrion to becoming one of Ireland's top three corporate finance and stockbroking firms in less than 6 years, before successfully selling it for approximately €100 million in 2006. Harry Thomas Stratford (aged 68), Non-executive Director and proposed Non-Executive Chairman Mr Stratford has over 40 years' experience in the pharmaceutical industry and has built two successful publicly listed pharmaceutical companies. Mr Stratford founded Shire Plc in 1986 and was CEO for almost a decade. Shire Plc grew from humble beginnings to be one of Europe's largest specialty pharmaceutical companies and its stock is a constituent of the FTSE100 index. Mr Stratford then went on to be founder, CEO and Executive Chairman of Prostrakan Plc, another international specialty pharmaceutical company, which was subsequently acquired by Kyowa Hakko Kirin of Japan in 2011. Mr Stratford holds a BSc. in Chemistry from the University of London and was awarded an OBE in the 2007 New Year's Honours list for his contribution to the Scottish Life Sciences Industry.

Kev4 by big guns I implied the board and senior management. Involved rather than behind would of been more appropriate. They are cut above most of the AIM dross. A highly experienced management team - The New Board and senior management is comprised of experienced industry participants including: · Harry Stratford, Chairman, is the founder of Shire plc, now a FTSE 100 biopharmaceutical company, and ProStrakan Group plc · Joseph Wiley, CEO, has over 20 years' experience in healthcare investment and pharmaceutical operational roles · Rory Nealon, CFO and COO, has spent the last 13 years as both CFO and then COO of Trinity Biotech PLC, a NASDAQ listed company · Michele Bellandi, CCO, is the former Head of Commercial Europe for Shire AG International and has held senior marketing roles at Serono and Eli Lilly · Ray Stafford, a Non-Executive Director, previously EVP of Global Marketing for Forest Laboratories which was listed on NYSE prior to being acquired for approximately US$28 billion · James Culverwell, a Non-Executive Director, previously head of European pharmaceutical equity research at Merrill Lynch in London until 2005. Current Directors Cathal Martin Friel (aged 51), Non-Executive Chairman and proposed Non-executive Director Mr Friel is managing director and one of the founders of Raglan Road Capital Limited (which trades as Raglan Capital), a Dublin and London based corporate finance and merchant banking group. Mr Friel has over 25 years of managerial, entrepreneurial and corporate finance experience, as well as successfully advising major UK and Irish companies on domestic and international transactions. He was previously one of the founding directors of Dublin based Merrion Corporate Finance, where he helped build Merrion to becoming one of Ireland's top three corporate finance and stockbroking firms in less than 6 years, before successfully selling it for approximately €100 million in 2006. Harry Thomas Stratford (aged 68), Non-executive Director and proposed Non-Executive Chairman Mr Stratford has over 40 years' experience in the pharmaceutical industry and has built two successful publicly listed pharmaceutical companies. Mr Stratford founded Shire Plc in 1986 and was CEO for almost a decade. Shire Plc grew from humble beginnings to be one of Europe's largest specialty pharmaceutical companies and its stock is a constituent of the FTSE100 index. Mr Stratford then went on to be founder, CEO and Executive Chairman of Prostrakan Plc, another international specialty pharmaceutical company, which was subsequently acquired by Kyowa Hakko Kirin of Japan in 2011. Mr Stratford holds a BSc. in Chemistry from the University of London and was awarded an OBE in the 2007 New Year's Honours list for his contribution to the Scottish Life Sciences Industry.

needed badly here as PEL don't do blow your own trumpet type RNS's if decent and expectations are met or exceeded it will restore investor confidence Many investors here still cautious after the companys last projections were below the markets expectations which tanked the sp forcing many investors to sell at a big loss or like myself stay locked in and wait for a recovery.

good point My concern is if we are able to relist on the AIM exchange If not would we be demoted to ISDX and how easy would it be to trade our shares there

The big guns are well behind this Once they kick on this will fly think they will start moving sooner than you think multi multi multi bagger here

to the potential of our new baby MelodyVR initial reaction was that don't impress me much but people waking up to how big this could be the next big thing be there on stage at the gig with your favourite band

of this relisting on another exchange other than AIM so we can trade our shares? could it go over to NASDAQ?

thats why the taxman decided to take $2.4 mill from their account as they didn't take the taxmans calls or reply to their emails

In line with the new strategy, post period end, in March 2016, the Company raised US$5m via a private placing of new ordinary shares in the Company at a price of 0.325p (KES 0.48) per share. The proceeds of the placing are primarily being allocated to finance the development of our industrial division, in particular advancing the Chancho Project. We the finance raised in March have they still got enough cash in the coffers to continue and crack on with the bottling plant or will this project collapse as well now? I can see another fund raiser coming here for $2.4million lol I would say if AAI recover these costs, maybe they'll get something back

sp not moved much wait for results and if decent sp should move up nicely

must be spending a fortune on RNS one every 5 mins

cheers guys Hopefully the Teathers Action Group can bring these rotters to their senses and ensure they do whats best for shareholders and hand back what they haven't already peed up the wall

Schroders plc & Schroder Investment Management Limited fancy a bit of Be Heard

partnering up with livenation http://blog.sfgate.com/techchron/2016/05/09/soon-youll-be-able-to-attend-concerts-using-vr/ maybe melodyvr will do the same with another live music promoter

what we expecting? positive for the sp? seems stuck in 9-10p will it ever move out of this range apart from the odd spike here and there like the one i bought in at last year

that just invested $5 million in the placing at .325 will love this news anyone know how much cash they have if they don't get any of the $2.4mill back

Atlas (AIM, NSE: ADSS) hereby provides an update regarding recent action taken by the Ethiopian Revenue and Customs Authority ("ERCA") in relation to Atlas and its Ethiopian subsidiary, TEAP Glass PLC ("TEAP"). ERCA's actions against Atlas and TEAP which are detailed below stem from a recently issued tax claim made against Ardan Risk & Support Services ("Ardan") which relates to periods prior to Atlas' involvement with Ardan (2010-2013). Atlas has received local legal advice that neither it nor TEAP has any liability for any such taxes under Ethiopian law. The Company has been advised by its local team in Addis Ababa that on 10 May 2016, ERCA summarily removed approximately US$2.4m from TEAP's bank account with the Development Bank of Ethiopia. Atlas will take all available steps to ensure that the Company's funds are returned. The Company is investigating these matters as a matter of urgency but based on initial feedback believes that the unilateral removal of these funds was unlawful and was in breach of an agreement reached with ERCA. The Board assures shareholders that it will take all available steps to ensure that the Company's funds are returned and the Board is currently exploring legal, diplomatic and political routes in order to seek redress. A further announcement will be made in due course.

on these crooks will we see any of our hard earned wonga again?